Gates-Backed Vir Biotechnology Flops in Trading Debut

(Bloomberg) -- Vir Biotechnology Inc. fell almost 30% in its trading debut, adding to a series of IPO disappointments in an industry that was seen as at least partly immune to the ills afflicting t...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.